Eikon plans IPO to bankroll clutch of clinical cancer drugs
18 hours ago · Eikon Therapeutics is planning to become the second biotech to go public in 2026 in another sign the public markets are looking increasingly attractive to drug developers. Eikon …
Eikon, a high-profile startup led by Merck vets, seeks an IPO
2 days ago · Eikon, a high-profile startup led by Merck vets, seeks an IPO Run by Roger Perlmutter and backed by more than $1 billion in private funding, Eikon will use the IPO …
Refinitiv Eikon
View the recommended PC requirements for Refinitiv Eikon. Ensure your computer and network meet the requirements to install and run Refinitiv Eikon. Compare features with the desktop …
Eikon Therapeutics Files for IPO Led By Merck Veterans
3 days ago · Eikon Therapeutics Inc. filed for an initial public offering to help fund its advanced pipeline of cancer drugs.
Eikon files for IPO after raising more than $1 billion from ...
3 days ago · Eikon Therapeutics filed for a Nasdaq IPO after raising $1.1 billion for cancer drugs, led by ex-Amgen and Merck exec Roger Perlmutter.
Eikon Therapeutics IPO Signals Biotech Market Revival
1 day ago · Eikon Therapeutics, a privately held biotechnology company founded by former Merck executives, has taken a decisive step toward the public markets. The high-profile startup …
Biopharmaceutical firm Eikon Therapeutics files for US IPO - MSN
Eikon Therapeutics is a late-stage clinical biopharmaceutical firm developing innovative medicines for serious unmet medical needs, with an initial focus on oncology.